INSERM UMR 1033, Université de Lyon, France.

Pathophysiology, Diagnosis & Treatments of Bone Diseases


Osteoporosis and bone metastasis induce structural alterations of the skeleton that lead to bone destruction and occurrence of pathological fractures. Despite of recent progress made to treat bone loss, there is clearly a need to better diagnose bone diseases and improve treatments of skeletal complications associated with bone diseases.


Our project aims at developing a translational research from basic scientific discoveries into clinical improvements in diagnosis and treatments of bone diseases.

Our scientific strategy hinges on 3 teams.

Team 1’s major objectives are to improve the prediction of fracture risk in men and women with osteoporosis. The relations between bone and certain chronic diseases will be also studied. It has become obvious (albeit little understood) that bone quality is influenced by chronic diseases and, conversely, that bone remodeling participates in the genesis of chronic diseases.

Team 2’s main objectives are to identify the underlying molecular mechanisms governing the nesting of tumour cells in the bone marrow and those that favour the formation of medullary micrometastases, the prelude required for bone metastasis formation. Additionally, new biological markers of early relapse of cancer in bone will be developed and novel therapeutics are being tested in animal models of malignant bone diseases.

Team 3’s main objectives are to study the roles of autotaxin and lysophosphatidic acid in bone physiology and benign (osteoporosis, rheumatoid arthritis) and cancerous (bone metastasis) bone pathologies.



Bone and chronic diseases



Bone, Cancers and Metastases



Lysophospholipids and Bone Pathophysiology

Short description
of the lab in figures:

  • Staff: 57
  • Basic and clinical scientists: 28
  • Research Engineers and Technicians: 18
  • Postdoctoral fellows and research students: 11


Recent News

6 key most recent publications :

  • Chapurlat R, Bui M, Sornay-Rendu E, Zebaze R, Delmas PD, Liew D, Lespessailles E, Seeman E. Deterioration of Cortical and Trabecular Microstructure Identifies Women With Osteopenia or Normal Bone Mineral Density at Imminent and Long-Term Risk for Fragility Fracture: A Prospective Study. J Bone Miner Res. 2019 Dec 10. doi: 10.1002/jbmr.3924.
    Download PDF
  • Feurer E, Kan C, Croset M, Sornay-Rendu E, Chapurlat R. Lack of Association Between Select Circulating miRNAs and Bone Mass, Turnover, and Fractures: Data From the OFELY Cohort. J Bone Miner Res. 2019 Jun;34(6):1074-1085.
    Download PDF
  • BOUCHET M, LAINÉ A, BOYAULT C, PROPONNET-GUERAULT M, MEUGNIER E, BOUAZZA L, KAN CWS, GERACI S, EL-MOGHRABI S, HERNANDEZ-VARGAS H, BENETOLLO C, YOSHIKO Y, DUTERQUE-COQUILLAUD M, CLÉZARDIN P, MARIE JC, BONNELYE E. ERRα expression in bone metastases leads to an exacerbated anti-tumor immune response. Cancer Res. 2020 May 4. pii: canres.3584.2019. doi: 10.1158/0008-5472.CAN-19-3584.
    Download PDF
  • VARGAS G, BOUCHET M, BOUAZZA L, REBOUL P, BOYAULT C, GERVAIS M, KAN C, BENETOLLO C, BREVET M, CROSET M, MAZEL M, CAYREFOURCQ L, GERACI S, VACHER S, PANTANO F, FILIPITS M, DRIOUCH K, BIECHE I, GNANT M, JACOT W, AUBIN JE, DUTERQUE-COQUILLAUD M, ALIX-PANABIÈRES C, CLÉZARDIN P, BONNELYE E. ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. Oncogene. 2019 Feb;38(7):950-964. doi: 10.1038/s41388-018-0579-3.
    Download PDF
  • Alioli CA, Demesmay L, Laurencin-Dalacieux S, Beton N, Farlay D, Follet H, Saber A, Duboeuf F, Chun J, Rivera R, Bouvard D, Machuca-Gayet I, Salles JP, Gennero I, Peyruchaud O. Expression of the type 1 lysophosphatidic acid receptor in osteoblastic cell lineage controls both bone mineralization and osteocyte specification. Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Apr 21;1865(8):158715. doi: 10.1016/j.bbalip.2020.158715.
    Download PDF
  • Flammier S, Peyruchaud O, Bourguillault F, Duboeuf F, Davignon JL, Norman DD, Isaac S, Marotte H, Tigyi G, Machuca-Gayet I, Coury F. Osteoclast-Derived Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss. Arthritis Rheumatol. 2019 Nov;71(11):1801-1811. doi:10.1002/art.41005.
    Download PDF